Thursday 16 October, 2025
An expert meeting to discuss issues relating to design of population pharmacokinetic/pharmaco-dynamic (PK/PD) studies was held in Brussels in March…
Read moreoral presentation
A Population Pharmacodynamics Model Of Recombinant Human Erythropoietin In Athletes
Thursday 16 October, 2025
The pharmacokinetic parameters of recombinant human erythropoietin (rHuEpo) were initially determined in healthy volunteers after a single subcutaneous administration of…
Read morePresentation Of Population Analyses For Regulatory Submissions
Thursday 16 October, 2025
The description of the implementation of the population approach for data analysis, either in a protocol or in a final…
Read moreInter-Occasion Variation In The Bioavailability Of Benflumetol (An Anti Malarial Drug)
Thursday 16 October, 2025
Artemether and Benflumetol are two efficacious and well tolerated anti malarial drugs developed and registered in China. The concomitant administration…
Read moreHormone exposure and effects on Follicle-Stimulating Hormone (FSH) after nasal administration of Estradiol (E2) in postmenopausal women
Thursday 16 October, 2025
Objective: This pharmacokinetic study was designed to characterize the pharmacokinetic (PK) profile of Estradiol (E2) and Estrone (E1), in order…
Read moreLOQ, a relic of the past?
Thursday 16 October, 2025
A reliable calculation of pharmacokinetic parameters for drugs is of high importance. In the recent years newly developed drugs have…
Read moreEstimating Individual Pretreatment Levels Of A Pharmacologic Response Variable
Thursday 16 October, 2025
When drug treatment affects a variable that is also measurable without treatment, e.g. blood pressure, heart rate, or the concentration…
Read moreCircadian Population Pharmacokinetics of 5-Fluorouracil (5-FU) in Patients with Metastatic Colorectal Cancer
Thursday 16 October, 2025
Purpose: To estimate the population pharmacokinetic parameters of 5-FUin patients with advanced colorectal cancer using circadian changekinetics . Patients and…
Read moreA Bayesian Analysis of Categorical and Count Pharmacodynamic Data
Thursday 16 October, 2025
Being able to define a therapeutic window for a particular drug is an important requirement for the design of safe…
Read moreEstimating potency for the Emax-model without attaining maximal effects
Thursday 16 October, 2025
The most widely applied model relating drug-concentrations to effects is the Emax model. In practice, concentration-effect relationships often deviate from…
Read more